Fate Therapeutics Inc FATE:NASDAQ

Last Price$32.21Cboe Closing Price as of 4:00PM ET 5/28/20
Cboe Real-Time Quotes
Today's Change-0.88(2.66%)
Bid (Size)$30.00 (24)
Ask (Size)$34.85 (2)
Day Low / High$32.09 - 34.31
Volume587.9 K
  • Latest Stories
  • Commentary and Analysis
Fate Therapeutics Wins FDA OK of Investigational New Drug Application for FT538 Cancer Cell Therapy
8:59AM ET 5/20/2020 MT Newswires

Fate Therapeutics (FATE) said premarket Wednesday its investigational new drug application for FT538, a potential cancer cell immunotherapy treatment, has...

Analyst Actions: HC Wainwright Resumes Fate Therapeutics at Buy With $42 Price Target
11:01AM ET 5/13/2020 MT Newswires

Fate Therapeutics (FATE) has an average analyst rating of buy, with an average price target of $36. Price: 27.32, Change: -1.43, Percent Change: -4.97 ...

Analyst Actions: BMO Capital Lifts Fate Therapeutics PT to $29 From $28, Maintains Market Perform Rating
12:06PM ET 5/12/2020 MT Newswires

Fate Therapeutics' (FATE) average rating among analysts is a buy, with an average price target of $36. Price: 31.01, Change: +0.79, Percent Change: +2.61...

Fate Therapeutics Reports Wider Q1 Loss, Flat Revenue
5:15PM ET 5/11/2020 MT Newswires

Fate Therapeutics (FATE), a US company, reported after markets closed on Monday Q1 loss of $0.44 per share, wider than $0.30 loss per share reported a year...

MT Newswires After-Hours News Movers
5:54PM ET 4/28/2020 MT Newswires

Some of the stocks moving on news-driven events in Tuesday's after-hours include: BXMT, +8.63% GOOGL, +7.98% TNET, +7.72% HELE, +7.68% WW, +7.67% ERYP,...

Fate Therapeutics Adds 2% On New Study Data
4:42PM ET 4/28/2020 MT Newswires

Fate Therapeutics (FATE) rose 2% after the company said data on a new off-the-shelf, iPSC-derived, chimeric antigen receptor (CAR)-targeted cell-based...

Analyst Actions: Oppenheimer Cuts Fate Therapeutics' Price Target to $34 From $36, Keeps Outperform Rating
9:37AM ET 4/06/2020 MT Newswires

Fate Therapeutics (FATE) has an average buy rating among analysts with an average price target of $36. Price: 24.37, Change: +1.43, Percent Change: +6.22...

--Analyst Actions: Wedbush Lifts Fate Therapeutics' PT to $41 from $38; Maintains Outperform Rating
10:26AM ET 4/03/2020 MT Newswires

Price: 23.70, Change: +2.63, Percent Change: +12.48 ...

Sector Update: Most Health Care Giants Retreat Pre-Bell Friday
9:08AM ET 4/03/2020 MT Newswires

Top Health Care Stocks: JNJ: -0.16% PFE: +0.30% ABT: -0.26% MRK: -0.48% AMGN: -0.42% Most health care giants were retreating pre-bell Friday. Early movers...

Fate Therapeutics, Janssen to Develop Cancer Immunotherapies; Starts Patient Dosing in Trial of FT596
6:31AM ET 4/03/2020 MT Newswires

Fate Therapeutics (FATE) said late Thursday it has entered into a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson (JNJ), to develop...